Noble Capital Markets Rates Unicycive Therapeutics (UNCY) buy

Noble Capital Markets has reiterated its buy rating for Unicycive Therapeutics with a $50 price target, a 937.62% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 10:00 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Noble Capital Markets rated Unicycive Therapeutics, Inc. ($UNCY) "buy" with a $50 price target on July 1, 2026.

Since the rating, $UNCY is up 2.8% after 1 week, down 5.1% after 1 month and down 36.4% to date (from the $5.28 close on Jul 1, 2026).

UNCY Unicycive Therapeutics, Inc.

$3.36 -42.07% year to date

Daily close · Oct 16, 2026

Key Points

Noble Capital Markets reaffirmed its buy rating on Unicycive Therapeutics, setting a price target of $50.00 on July 1, 2026.
As of July 1, 2026, Unicycive's stock trades at $4.82, significantly below the target price, suggesting substantial potential upside.
The average analyst target for Unicycive is currently $29.6, with ten analysts providing opinions on the stock.

Get $UNCY trade alerts by text

We text you when insiders, Congress or big funds trade $UNCY. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Unicycive Therapeutics, Inc. alert may contain errors. Disclosures

Noble Capital Markets Reiterates Buy Rating

Noble Capital Markets has reiterated its buy rating on Unicycive Therapeutics, Inc. (NasdaqCM: UNCY), setting a target price of $50.00. This announcement was made on July 1, 2026. The stock is currently trading at $4.82, which is well below the target price, indicating a significant potential upside for investors.

Analysts Set New Price Targets

Noble's rating reflects a strong belief in Unicycive's future performance. The target price of $50.00 suggests that analysts see considerable growth potential, especially since the stock is currently trading much lower. This is the second buy rating issued by Noble Capital Markets in a short time, indicating confidence in the company's prospects.

Other Analyst Opinions

On the same day, Benchmark maintained its speculative buy rating for Unicycive Therapeutics, setting a lower target of $13.00, down from $15.00. Additionally, HC Wainwright & Co. also kept its buy rating with a target of $15.00. These varying targets from different firms highlight differing views on the stock's potential, with Noble's target being the highest.

Stock Performance Context

Unicycive shares are currently trading at $4.82, near its 52-week low of $3.71. This low trading price may attract investors looking for bargains, especially given the positive ratings from analysts. The stock has a 52-week high of $8.74, suggesting that there is room for recovery and growth if the company's developments succeed.

12-month forecast

$UNCY price target

Unicycive Therapeutics, Inc. daily closes and this analyst's $50 target. Not advice.

What Unicycive Therapeutics, Inc. Does

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company based in Mountain View, California. It focuses on developing treatments for kidney diseases, including therapies that are currently in various stages of clinical trials. The company's innovative approach positions it well in a critical healthcare sector.

What to Watch at Unicycive Therapeutics, Inc.

Investors will be watching Unicycive's next earnings report, scheduled for November 12, 2026. With the stock trading well below analyst targets, further updates on clinical trials and company developments could influence its market performance. As a reminder, analyst ratings reflect opinions based on past performance and may not represent current positions.